Advertisement
U.S. Markets closed

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
50.69-0.07 (-0.14%)
At close: 03:00PM CST
Full screen
Previous Close50.76
Open50.83
Bid50.68 x 0
Ask50.69 x 0
Day's Range50.14 - 51.18
52 Week Range35.51 - 57.53
Volume37,059,732
Avg. Volume32,907,339
Market Cap323.351B
Beta (5Y Monthly)0.29
PE Ratio (TTM)58.94
EPS (TTM)0.86
Earnings DateOct 25, 2024
Forward Dividend & Yield0.20 (0.39%)
Ex-Dividend DateJul 12, 2024
1y Target Est56.85
  • Bloomberg

    US Venture Capital Opens Path to Funding for China Biotech Firms

    (Bloomberg) -- Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese biotechnology companies have found a new way to cash in on their innovative therapies.Most Read from BloombergUrban Heat Stress Is Another Disparity in the World’s Most Unequal NationFrom Cleveland to Chicago, NFL Teams Dream of Domed StadiumsSingapore Ends 181 Years of Horse Racing to Make Way for HomesChicago’s $1 Billion Budget Hole Exacerbated by School Turmoi

  • Clinical Trials Arena

    ESMO 2024: Can Jiangsu Hengrui Pharma disrupt the HER2-mGEJ treatment paradigm?

    Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a challenge.